Celsion Reports that Sufficient Events Have Been Reached for the Second Interim Analysis of the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer Independent Data Monitoring Committee is Expected to Meet in July 2020 to Evaluate Overall Survival Data LAWRENCEVILLE, N.J., April 15, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:...